How Long Do You Take Wegovy for Weight Loss? The Real Treatment Timeline

Key Takeaways

• Wegovy is approved for chronic, indefinite use. The label does not specify a stop date because obesity is treated as a chronic condition similar to high blood pressure or diabetes (FDA Wegovy label, 2024).
• The full titration to the maintenance dose of 2.4 mg takes 16 to 20 weeks. Most weight loss happens between months 4 and 16.
• In the STEP 4 trial, patients who stopped Wegovy at week 20 regained two-thirds of their lost weight within 1 year (Rubino et al., JAMA 2021).
• Most patients who maintain weight loss long-term stay on Wegovy at the maintenance dose or step down to a lower maintenance dose.
• Plan for at least 12 months of treatment to reach a stable maintenance phase. Expect to be on the medication, in some form, indefinitely if you want to keep the weight off.

Direct answer (40-60 words)

Wegovy is taken indefinitely for chronic weight management, the same way medications for high blood pressure or diabetes are taken long-term. The standard plan: 16 to 20 weeks of titration to the 2.4 mg maintenance dose, then ongoing maintenance. Patients who stop Wegovy regain about two-thirds of lost weight within 1 year per the STEP 4 trial.

Table of contents

1. The 30-second answer
2. The full Wegovy treatment timeline (week-by-week)
3. What happens to your weight after you stop Wegovy
4. The case for indefinite treatment
5. The case for treatment breaks or step-down
6. How to know you've hit your goal weight
7. Maintenance dose options
8. Insurance coverage and cost over time
9. When tapering off makes sense
10. FAQ
11. Sources

The full Wegovy treatment timeline (week-by-week)

Wegovy is escalated through 5 dose steps over 16 weeks before reaching the 2.4 mg maintenance dose. Each step is held for 4 weeks:

The 2.4 mg dose is the target. Some patients can't tolerate the full escalation due to nausea or other side effects and stay at 1.7 mg or 1.0 mg as their personal maintenance dose. Lower doses produce less weight loss but may be more tolerable long-term.

After week 17, weight loss continues at a slower pace. The STEP 1 trial (Wilding et al., NEJM 2021) showed continued weight loss through week 68, with the trajectory flattening around month 14 to 16. By the time most patients hit the 1-year mark, they've lost roughly 12 to 16 percent of starting body weight.

After year 2, weight loss is minimal and the medication's role shifts from active loss to weight maintenance. The STEP 5 trial (Garvey et al., Nature Medicine 2022) followed patients for 2 years and found that weight loss stabilized at around 15 percent of baseline weight, with minimal regain on continued treatment.

What happens to your weight after you stop Wegovy

This is the most important data point in the field, and the one most people don't want to hear.

The STEP 4 trial (Rubino et al., JAMA 2021) followed two groups after 20 weeks of Wegovy escalation:

• Group A continued Wegovy 2.4 mg for 48 more weeks
• Group B switched to placebo for 48 more weeks

By week 68:

• Group A (continued Wegovy): an additional 7.9 percent weight loss on top of the 10.6 percent already lost
• Group B (switched to placebo): regained 6.9 percent of body weight, ending at 5.0 percent below baseline

In other words, patients who stopped Wegovy regained two-thirds of the weight they'd lost. Those who continued kept losing.

The STEP 1 follow-up extension (Wilding et al., Diabetes, Obesity and Metabolism 2022) tracked patients for 1 year after they stopped semaglutide and found similar regain: by 1 year off-treatment, patients had regained an average of 11.6 of the 17.3 percentage points they'd lost.

The pattern is consistent across all major GLP-1 trials. The drug works while you're on it. Most of the weight comes back when you stop.

This isn't a willpower issue. The mechanisms behind weight regain are biological: appetite hormones (ghrelin, GLP-1, peptide YY) shift back toward pre-treatment levels, gastric emptying speeds up again, and the body's set-point pressure to regain weight reasserts itself. The same pattern is seen after surgical weight loss when adherence to post-surgery protocols breaks down.

The case for indefinite treatment

Obesity is recognized as a chronic disease by the World Health Organization, the American Medical Association (since 2013), and the National Institutes of Health. Chronic diseases require chronic treatment. The argument for indefinite Wegovy use rests on three points:

Point 1: The biology doesn't change. Whatever genetic, metabolic, or environmental factors contributed to obesity in the first place are still present after weight loss. The medication is treating the chronic condition. Stopping the medication is the same as stopping a blood pressure pill: the underlying physiology returns.

Point 2: The cardiovascular benefit accumulates over time. The SELECT trial (Lincoff et al., NEJM 2023) showed that semaglutide 2.4 mg reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20 percent over a median 3.3 years of treatment in patients with established cardiovascular disease. The benefit kept growing across the trial. Discontinuing treatment likely loses that protection.

Point 3: Long-term safety data is reassuring. Semaglutide has been in widespread use since 2017 (as Ozempic for diabetes) and 2021 (as Wegovy for obesity). The major safety signals (pancreatitis, gallbladder disease, thyroid C-cell tumors in rodents) have been studied across millions of patient-years without new red flags emerging. The drug is safe enough for indefinite use in eligible patients.

The American Society of Endocrinology, the Obesity Medicine Association, and most academic obesity specialists now recommend treating obesity medications as chronic therapy unless side effects or other factors require discontinuation.

The case for treatment breaks or step-down

Indefinite treatment isn't always feasible or desirable. Real reasons patients pause or stop:

Reason 1: Cost. Wegovy at full price is roughly $1,300 per month, or roughly $15,600 per year. With manufacturer savings cards, commercial insurance can bring this to $0 to $25 per month, but coverage is unreliable. If insurance changes or coverage is dropped, patients often can't afford to continue.

Reason 2: Side effects. A small percentage of patients have persistent nausea, reflux, fatigue, or other side effects that don't resolve. For these patients, dose reduction or treatment breaks are reasonable.

Reason 3: Pregnancy planning. Wegovy is not recommended during pregnancy. Patients planning pregnancy should stop Wegovy at least 2 months before trying to conceive (per the FDA label) and stay off during pregnancy and breastfeeding.

Reason 4: Reaching a goal and wanting to test maintenance without medication. Some patients want to know if they can maintain weight loss with diet, exercise, and behavioral change alone. The answer for most is no, but some patients do maintain successfully off-drug, especially with intensive lifestyle support.

Reason 5: Surgery or hospitalization. Wegovy should be paused before any surgery requiring general anesthesia (per the American Society of Anesthesiologists guidance, 2023, due to delayed gastric emptying and aspiration risk). Most surgeons request a 1-week pause before surgery.

For patients who do step down or pause, two strategies show modest success at preserving weight loss:

• Step-down to a lower maintenance dose (1.7 mg or 1.0 mg) rather than full discontinuation
• Intensive lifestyle support (registered dietitian, structured exercise program, behavioral therapy) during and after the taper

How to know you've hit your goal weight

The published trials and the FDA label are silent on a specific stop point. There's no "you've succeeded, now you can stop" signal.

Reasonable goal markers include:

• BMI under 25 (normal weight) or under 30 (no longer obese)
• Waist circumference under 40 inches for men, 35 inches for women (per AHA cardiometabolic risk thresholds)
• Resolution of weight-related comorbidities (e.g., type 2 diabetes remission, sleep apnea resolution, fatty liver normalization)
• Stable weight for 3 to 6 consecutive months at a level you're satisfied with

Hitting these markers means the medication has done its job for the active weight-loss phase. The question is no longer "can I lose weight" but "can I maintain it."

The published evidence on maintenance off-drug is poor. Most patients regain. The realistic path for most is continued treatment at a maintenance dose, not discontinuation.

Maintenance dose options

Three common maintenance approaches:

Option A: Continued 2.4 mg weekly. The full FDA-labeled maintenance dose. Best for patients who want to continue losing past goal, who have cardiovascular indications, or who tolerate the full dose well. Highest cost.

Option B: Step-down to 1.7 mg weekly. Off-label but common in clinical practice. Roughly 75 to 85 percent of the appetite-suppression effect at lower nausea risk. Cheaper if pharmacy fills lower-dose pens.

Option C: Step-down to 1.0 mg weekly. Off-label and less established for weight maintenance. Some patients maintain on this dose with adequate diet and exercise support. Roughly 50 to 65 percent of the appetite-suppression effect.

Option D: Bi-weekly or extended-interval dosing. Off-label and not well-studied. Some patients dose every 10 to 14 days at the maintenance phase to extend supply and reduce cost. Not recommended without provider supervision.

Choice depends on goals, cost, side effects, and provider preference. There's no single right answer.

Insurance coverage and cost over time

Year 1 (titration plus partial maintenance):

• With manufacturer savings card and good commercial insurance: $0 to $300 total
• With commercial insurance only (no card): $1,200 to $4,800
• Cash pay: $14,000 to $16,000

Year 2 onward (maintenance only):

• Same range, depending on coverage
• Some insurers limit Wegovy coverage to 12 to 24 months, after which patients pay cash or switch options
• Manufacturer savings cards have annual benefit limits; check current terms

The structural problem: insurance often covers Wegovy aggressively in year 1, then loses interest in year 2 and beyond. Patients should plan for the possibility of paying more out-of-pocket starting in year 2.

If long-term continuation matters, ask early in treatment whether your plan has a duration limit on weight-loss medications. Some plans cap at 12 months of coverage. Others continue indefinitely as long as weight loss is documented.

When tapering off makes sense

Reasonable scenarios for tapering off Wegovy:

• You're planning pregnancy in the next 3 to 6 months
• You've reached goal weight and want to test maintenance with intensive lifestyle support
• Cost has become unsustainable and no other options apply
• You're experiencing side effects that don't resolve at lower doses

If you do taper off, the protocol most clinicians use:

1. Step down by one dose level every 4 to 6 weeks (e.g., 2.4 mg to 1.7 mg to 1.0 mg)
2. Increase nutrition support (registered dietitian, structured meal plan)
3. Track weight weekly; consider restarting if regain exceeds 5 percent
4. Add resistance training to preserve muscle mass

Sudden discontinuation isn't dangerous, but the gradual taper gives you a chance to adjust eating and activity as appetite returns.

FAQ

How long do you take Wegovy for weight loss? Wegovy is taken indefinitely for chronic weight management. The full titration to maintenance dose takes 16 to 20 weeks, then maintenance continues as long as the medication is appropriate, accessible, and tolerated. Most patients regain weight after stopping, so long-term use is the standard.

Can I stop Wegovy after I lose the weight? You can, but most patients regain about two-thirds of the lost weight within 1 year per the STEP 4 trial. If you stop, plan for intensive lifestyle support and weekly weight tracking. Be prepared to restart if regain occurs.

How long until Wegovy starts working? Most patients see appetite suppression within the first week and the first measurable weight loss within 4 weeks. Full effect requires 16 to 20 weeks of titration to the 2.4 mg maintenance dose.

How long is the Wegovy titration schedule? 16 weeks total. Five dose levels of 4 weeks each: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg. Patients who don't tolerate full escalation can stay at a lower dose as their personal maintenance dose.

How much weight can I lose on Wegovy in 6 months? The STEP 1 trial showed average weight loss of 9 to 11 percent of body weight at 6 months on the full titration schedule. Individual results vary by adherence, baseline weight, diet, and exercise.

How much weight can I lose on Wegovy in 1 year? The STEP 1 trial reported average weight loss of 14.9 percent at 68 weeks. About 32 percent of patients lost 20 percent or more of their body weight by 1 year.

Do you keep losing weight on Wegovy after 1 year? Mostly the trajectory flattens. The STEP 5 trial showed minimal additional weight loss between months 12 and 24, with weight stable at around 15 percent below baseline. The medication shifts to a maintenance role.

Can I take Wegovy long-term? Yes. Wegovy is approved for chronic use without a defined stop date. Long-term safety data through 3+ years is reassuring. Most obesity specialists recommend indefinite use unless side effects or other factors require stopping.

What happens if I stop Wegovy after 6 months? Most patients regain a substantial portion of the lost weight within 6 to 12 months of stopping. The STEP 4 trial showed about two-thirds regain by 1 year off-treatment. Lifestyle changes alone preserve modest weight loss for some patients but not most.

Is it safe to take Wegovy for years? Long-term safety data through 3+ years is reassuring. The major monitored side effects (pancreatitis, gallbladder disease, thyroid C-cell tumors in rodents) have not emerged as significant clinical signals in real-world use. Discuss long-term plans with your provider.

Can I take a break from Wegovy and restart? Yes, but plan carefully. If the break is short (less than 4 weeks), you can usually restart at the same dose. Longer breaks may require re-titration to avoid nausea and GI side effects. Talk with your provider before pausing.

Will insurance cover Wegovy long-term? Coverage varies. Many commercial plans cover year 1 aggressively, then add hurdles in year 2 (prior authorization, documented continued weight loss). Some plans cap coverage at 12 to 24 months. Confirm your plan's policy early so you can plan financially.

Sources

1. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
2. Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA. 2021;325:1414-1425.
3. Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28:2083-2091.
4. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obes Metab. 2022;24:1553-1564.
5. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
6. FDA. Wegovy (semaglutide) prescribing information. Novo Nordisk. Updated 2024.
7. American Society of Anesthesiologists. Consensus-based guidance on preoperative management of patients on GLP-1 receptor agonists. 2023.
8. Bray GA, et al. Management of obesity. Lancet. 2016;387:1947-1956.
9. Wadden TA, et al. Behavioral treatment of obesity. Endocrinol Metab Clin North Am. 2020;49:323-340.
10. American Heart Association. Cardiovascular disease and obesity: scientific statement. Circulation. 2021;143:e984-e1010.
11. Apovian CM, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:342-362.

Footer disclaimers (all 4 verbatim)

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.